Cyted uses unique AI-driven diagnostics to identify patients at risk of developing cancer. Their cancer detecting technology provides a quicker, more comfortable, and more accessible to identify those at risk of risk of oesophageal cancer that the current standard of care, which relies on an endoscopy procedure.

The NHS is offering this test to thousands of people suffering from symptoms of chronic reflux and the pre-cancerous condition Barrett’s Oesophagus each year.

Cyted collects, digitises, and analyses samples to help doctors detect early cancer. The early cancer test is currently used in more than 50 hospitals and community-based clinics.

The company’s proprietary AI technology, supported by clinicians, highlights biomarkers that indicate abnormality in cells which can lead to cancer. Their research and development team are developing the machine learning approach that drives this process to explore new diagnostic technologies.